Bharat Biotech Gets DCGI Panel's Approval For Phase 3 Trials Of Intranasal COVID-19 Vaccine As Booster Shot: ReportRepresentative Image

Bharat Biotech has obtained the approval from the Drugs Comptroller General of India (DCGI) for carrying out last-stage trials of its nasal Covid-19 vaccine as a form of booster shots, reports Moneycontrol.

The company had filed its last-stage trial application to the DCGI back in December as it maintained that there would be greater convenience in administering an intranasal vaccine during the mass vaccination campaign.

The drug regulator’s subject expert committee (SEC) has reportedly given an in-principle to Bharat Biotech for conducting the intranasal vaccine’s ‘Phase III superiority study and Phase III booster dose study’ in parallel in wake of the Covid situation in the country.

The development comes as the government had recently announced that Healthcare and frontline workers along with the elderly citizens will receive a ‘precautionary dose’ or a booster shot of the Covid-19 vaccine from 10th January onwards.

So far, Covishield manufactured by the Serum Institute of India (SII) along with Bharat Biotech’s Covaxin have largely dominated the massive vaccination drive carried out in India.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber